Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Affimed NV

AFMD
Current price
0.73 USD -0.015 USD (-2.03%)
Last closed 0.57 USD
ISIN NL0010872420
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 12 023 752 USD
Yield for 12 month -85.33 %
1Y
3Y
5Y
10Y
15Y
AFMD
21.11.2021 - 28.11.2021

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company's lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid. It develops AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. It has collaboration with Artiva Biotherapeutics to develop the combination of acimtamig and AlloNK; license and strategic collaboration agreement with Roivant Sciences Ltd. to develop and commercialize novel ICE molecules, including AFM32, in oncology; and strategic collaboration agreement with Genentech for the development of certain product candidates, which includes novel NK cell engager-based immunotherapeutics to treat multiple cancers. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Mannheim, Germany. Address: Gottlieb-Daimler-Straße 2, Mannheim, Germany, 68165

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

13.02 USD

P/E ratio

Dividend Yield

Current Year

+9 410 670 USD

Last Year

+47 028 332 USD

Current Quarter

+176 272 USD

Last Quarter

+175 135 USD

Current Year

+9 410 670 USD

Last Year

+47 028 332 USD

Current Quarter

+176 272 USD

Last Quarter

Key Figures AFMD

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -60 759 000 USD
Operating Margin TTM -8 709.15 %
Price to Earnings
Return On Assets TTM -49.42 %
PEG Ratio
Return On Equity TTM -149.49 %
Wall Street Target Price 13.02 USD
Revenue TTM 5 637 000 USD
Book Value 1.05 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY -91.60 %
Dividend Yield
Gross Profit TTM 5 637 000 USD
Earnings per share -5.14 USD
Diluted Eps TTM -5.14 USD
Most Recent Quarter III 2024
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics AFMD

Max Ratio

>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - expected <5 dividend yield on cost over 10Y MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Dividend History AFMD

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Ex Dividend Date
Dividend CAGR 3Y
Dividend CAGR 5Y
Dividend CAGR 10Y
Consecutive Years
Consistent Years
Continuous Dividends
Forward Annual Dividend Yield
Forward Annual Dividend – USD
Last Split Factor 1:10
Payout Ratio
Last Split Date 11.03.2024

Stock Valuation AFMD

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 13.07
Price Sales TTM 2.13
Enterprise Value EBITDA 1.13
Price Book MRQ 0.62

Financials AFMD

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators AFMD

For 52 weeks

0.52 USD 8.95 USD
50 Day MA 0.88 USD
Shares Short Prior Month 602 449
200 Day MA 2.63 USD
Short Ratio 7.22
Shares Short 590 706
Short Percent 3.82 %